Press Releases Home News Press Releases September 14, 2021 QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2 June 8, 2021 Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS May 26, 2021 QurAlis Boosts World-Class Leadership Team with Addition of Three New Members February 2, 2021 QurAlis Continues to Expand Leadership Team with Two Key Hires December 11, 2020 QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models December 2, 2020 QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND October 29, 2020 QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board July 1, 2020 QurAlis Announces Agreement to Strengthen ALS Pipeline May 13, 2020 QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) April 5, 2018 QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS
